• Product
  • Supplier
  • Inquiry


    Home > Chemial News > Pharma News > Policy escalation to impact China's antibiotics market

    Policy escalation to impact China's antibiotics market


    Recently, China's National Health Commission issued a Notice on Further Strengthening the Management of Anti-microbial Drugs to Curb Drug Resistance, which requires the standardization of drug treatment for infectious diseases caused by pathogenic microorganisms such as bacteria, mycoplasma, chlamydia, rickettsia, spirochetes, and fungi.

    Specifically, the Notice proposes that the rational use of anti-microbial drugs should be incorporated into hospital accreditation, public hospital performance appraisal, rational drug use assessment and other work, and appropriately increase the weight of the assessment requirements.

    In addition, the notice also proposed that medical institutions in accordance with the provisions of the scientific adjustment to optimize the supply of anti-microbial drugs catalog of the institution, from the source of procurement to do a good job of rational use of anti-microbial drug management. 2021 by the end of September, more than two general hospitals should all join the national antibacterial drug clinical application monitoring network and bacterial drug resistance monitoring network.

    It is worth noting that antibiotics are a very important class of anti-microbial drugs, including penicillins, cephalosporins, aminoglycosides, macrolides, tetracyclines, peptides, lincomycin, etc. For this reason, the industry believes that as the country further strong anti-microbial drug management, antibiotic drugs will also be further tight control, its market will usher in a big challenge.

    It is understood that antibiotics are mainly used to treat or prevent certain types of bacterial infections, and they can kill bacteria or stop their spread. Because they have created many medical miracles, many people treat antibiotics as "miracle drugs" or equivalent to "anti-inflammatory drugs", mistakenly believing that antibiotics can treat all inflammatory diseases. This is the reason why antibiotics have been abused for a long time in China, which has brought adverse reactions to human body.

    At present, under the continuous influence of "national antibacterial restriction policy", the growth rate of antibiotic hospital market sales is gradually slowing down. In addition, it is worth mentioning that, in this context, some antibiotic manufacturers have also begun to sell the business or accelerate the transformation. It is reported that on April 23, 2019, Eli Lilly and Company announced the signing of an agreement with the Chinese pharmaceutical company Yiteng Pharmaceutical to sell its antibiotic products to it. In addition, Kolon Pharmaceuticals began its transformation in 2012, and the proportion of its non-infusion products is now increasing.

    Industry analysts believe that, in the context of the country's increasing attention to drug safety issues, constantly strengthening the management of anti-microbial drugs, as well as increasing the weight of its assessment in hospital use, the future, although the antibiotic market will continue to expand, but at the same time it will also be subject to more stringent control.

    Share to:
    Disclaimer: Echemi reserves the right of final explanation and revision for all the information.

    Scan the QR Code to Share

    Send Message